Identifying a phenotypic spectrum in ALS patient-derived fibroblasts
We sought to compare changes in gene expression levels and pathway-level dysregulation between FUS-ALS, sporadic ALS, and healthy control patient derived fibroblasts. Gene expression profiling analysis were performed on bulk RNA-seq data obtained from 12 FUS, 11 sporadic, and 13 healthy control cell lines. Overall design: Comparative gene expression profiling analysis of RNA-seq data for FUS-ALS, sporadic ALS, and healthy control patient-derived fibroblasts. contributor: New York Genome Center ALS Consortium